Other
Prevention and Early Treatment of Acute Lung Injury (PETAL) Network
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed trials have results
Key Signals
3 with results
Enrollment Performance
Analytics
Phase 3
3(100.0%)
3Total
Phase 3(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT04843761Phase 3Completed
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Role: collaborator
NCT06729593Phase 3Completed
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Role: collaborator
NCT06729606Phase 3Completed
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Role: collaborator
All 3 trials loaded